Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5893-5899

  Satlin, Michael J ^a   Kubin, Christine J ^b   Blumenthal, Jill S ^c   Cohen, Andrew B ^c   Furuya, E Yoko ^d   Wilson, Stephen J ^a   Jenkins, Stephen G ^a   Calfee, David P ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CREATININE; GENTAMICIN; POLYMYXIN B; TIGECYCLINE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL CLEARANCE; BACTERIURIA; CARBAPENEM RESISTANT KLEBSIELLA PNEUMONIAE; CATHETER INFECTION; CLINICAL EFFECTIVENESS; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG DOSE REDUCTION; FEMALE; FEVER; FOLLOW UP; HUMAN; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; LENGTH OF STAY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PYURIA; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; TREATMENT DURATION; URINARY CATHETER; URINARY TRACT DISEASE; URINE CULTURE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MINOCYCLINE; POLYMYXIN B; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY TRACT INFECTIONS; URINE; YOUNG ADULT;

EID: 81555224261     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00387-11     Document Type: Article

References (28)

1. Anderson, K. F., et al. 2007. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J. Clin. Microbiol. 45: 2723-2725. (Pubitemid 47295515)
2. Anthony, K. B., et al. 2008. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin. Infect. Dis. 46:567-570. (Pubitemid 351263497)
3. Bratu, S., et al. 2005. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch. Intern. Med. 165:1430-1435. (Pubitemid 40973427)
4. Bratu, S., et al. 2005. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 49:3018-3020. (Pubitemid 40917631)
5. Bratu, S., et al. 2005. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J. Antimicrob. Chemother. 56:128-132. (Pubitemid 41418346)
6. Castanheira, M., H. S. Sader, L. M. Deshpande, T. R. Fritsche, and R. N. Jones. 2008. Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase- producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 52:570-573. (Pubitemid 351170830)
7. Charlson, M. E., P. Pompei, K. L. Ales, and C. R. MacKenzie. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383. (Pubitemid 17055592)
8. Cunha, B. A., B. McDermott, and S. Nausheen. 2007. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection. J. Chemother. 19:753-754. (Pubitemid 351212030)
9. Curcio, D. 2008. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective. J. Clin. Microbiol. 46:1892-1893. (Pubitemid 351657253)
10. Geerlings, S. E., K. A. van Donselaar-van der Pant, and I. Keur. 2010. Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. J. Antimicrob. Chemother. 65:2048-2049.
11. Gobin, P., F. Lemaitre, S. Marchand, W. Couet, and J. C. Olivier. 2010. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob. Agents Chemother. 54:1941-1948.
12. Hidron, A. I., et al. 2008. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011.
13. Kitchel, B., et al. 2009. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob. Agents Chemother. 53:3365-3370.
14. Krueger, W. A., et al. 2008. Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J. Clin. Microbiol. 46:817-820. (Pubitemid 351231347)
15. Lanao, J. M., J. L. Pedraz, A. S. Navarro, and A. Dominguez-Gil. 1984. Influence of dose in the urinary excretion of amikacin. Int. J. Clin. Pharmacol. Ther. Toxicol. 22:538-542. (Pubitemid 14003623)
16. Li, J., et al. 2004. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J. Antimicrob. Chemother. 53:837-840. (Pubitemid 38660288)
17. Mehta, R. L., et al. 2007. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 11:R31.
18. Mendes, C. A., J. A. Cordeiro, and E. A. Burdmann. 2009. Prevalence and risk factors for acute kidney injury associated with parenteral polymyxin B use. Ann. Pharmacother. 43:1948-1955.
19. Nordmann, P., G. Cuzon, and T. Naas. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236.
20. Pastewski, A. A., et al. 2008. Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: a retrospective case series. Ann. Pharmacother. 42:1177-1187.
21. Reid, G. E., S. A. Grim, C. A. Aldeza, W. M. Janda, and N. M. Clark. 2007. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27:1198-1201.
22. Rello, J. 2005. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J. Chemother. 17(Suppl. 1):12-22. (Pubitemid 41686777)
23. Streit, J. M., R. N. Jones, H. S. Sader, and T. R. Fritsche. 2004. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY Antimicrobial Surveillance Program (North America, 2001). Int. J. Antimicrob. Agents 24:111-118. (Pubitemid 38993688)
24. Vasilevskis, E. E., et al. 2009. Mortality probability model III and simplified acute physiology score II: assessing their value in predicting length of stay and comparison to APACHE IV. Chest 136:89-101.
25. Vidal, L., et al. 2007. Efficacy and safety of aminoglycoside monotherapy: systematic review and meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 60:247-257. (Pubitemid 47243870)
26. Wilson, T. W., W. A. Mahon, T. Inaba, G. E. Johnson, and D. Kadar. 1973.
27. Elimination of tritiated gentamicin in normal human subjects and in patients with severely impaired renal function. Clin. Pharmacol. Ther. 14:815-822.
28. Zavascki, A. P., et al. 2008. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin. Infect. Dis. 47:1298-1304.